🚀 VC round data is live in beta, check it out!
Tiziana Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tiziana Life Sciences and similar public comparables like Curatis Holding, Heidelberg Pharma, Tenaya Therapeutics, Medivir and more.
Tiziana Life Sciences Overview
About Tiziana Life Sciences
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.
Founded
1998
HQ
Employees
9
Website
Sectors
Financials (FY)
EV
$143M
Tiziana Life Sciences Financials
Tiziana Life Sciences reported last fiscal year revenue of — and negative EBITDA of ($17M).
In the same fiscal year, Tiziana Life Sciences generated ($17M) in EBITDA losses and had net loss of ($12M).
Revenue (LTM)
Tiziana Life Sciences P&L
In the most recent fiscal year, Tiziana Life Sciences reported revenue of — and EBITDA of ($17M).
Tiziana Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($17M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($12M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tiziana Life Sciences Stock Performance
Tiziana Life Sciences has current market cap of $150M, and enterprise value of $143M.
Market Cap Evolution
Tiziana Life Sciences' stock price is $1.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $143M | $150M | -6.3% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTiziana Life Sciences Valuation Multiples
Tiziana Life Sciences trades at (8.6x) EV/EBITDA.
Tiziana Life Sciences Financial Valuation Multiples
As of April 11, 2026, Tiziana Life Sciences has market cap of $150M and EV of $143M.
Equity research analysts estimate Tiziana Life Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tiziana Life Sciences has a P/E ratio of (12.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $150M | XXX | $150M | XXX | XXX | XXX |
| EV (current) | $143M | XXX | $143M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (8.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (9.1x) | XXX | XXX | XXX |
| P/E | — | XXX | (12.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (92.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tiziana Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tiziana Life Sciences Margins & Growth Rates
Tiziana Life Sciences' revenue in the last fiscal year grew by —.
Tiziana Life Sciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.8M for the same period.
Tiziana Life Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (3%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.8M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tiziana Life Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Curatis Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Heidelberg Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Tenaya Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Medivir | XXX | XXX | XXX | XXX | XXX | XXX |
| Galectin Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tiziana Life Sciences M&A Activity
Tiziana Life Sciences acquired XXX companies to date.
Last acquisition by Tiziana Life Sciences was on XXXXXXXX, XXXXX. Tiziana Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tiziana Life Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTiziana Life Sciences Investment Activity
Tiziana Life Sciences invested in XXX companies to date.
Tiziana Life Sciences made its latest investment on XXXXXXXX, XXXXX. Tiziana Life Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tiziana Life Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tiziana Life Sciences
| When was Tiziana Life Sciences founded? | Tiziana Life Sciences was founded in 1998. |
| Where is Tiziana Life Sciences headquartered? | Tiziana Life Sciences is headquartered in United States. |
| How many employees does Tiziana Life Sciences have? | As of today, Tiziana Life Sciences has over 9 employees. |
| Who is the CEO of Tiziana Life Sciences? | Tiziana Life Sciences' CEO is Kunwar Shailubhai. |
| Is Tiziana Life Sciences publicly listed? | Yes, Tiziana Life Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Tiziana Life Sciences? | Tiziana Life Sciences trades under TLSA ticker. |
| When did Tiziana Life Sciences go public? | Tiziana Life Sciences went public in 2018. |
| Who are competitors of Tiziana Life Sciences? | Tiziana Life Sciences main competitors are Curatis Holding, Heidelberg Pharma, Tenaya Therapeutics, Medivir. |
| What is the current market cap of Tiziana Life Sciences? | Tiziana Life Sciences' current market cap is $150M. |
| Is Tiziana Life Sciences profitable? | No, Tiziana Life Sciences is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.